On Apr. 30, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitroﾔ, was submitted to an online peer-reviewed life sciences journal. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.